Comparing collagen injection to placebo for knee osteoarthritis
Official title: Hydrolyzed Collagen Formulation Versus Placebo in the Treatment of Degenerative Knee Cartilage Injuries
Run by Istituto Ortopedico Rizzoli · NCT04998188 · Data updated 2026-11-12
This study is testing if a single injection of collagen can help people with knee osteoarthritis feel better compared to a placebo shot.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 204 (estimated) |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | February 16, 2022 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT04998188 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with unilateral knee osteoarthritis who have not responded to conservative treatments.
✕Probably not a fit
Patients with recent knee surgeries, other significant medical conditions, or those who have received other intra-articular injections in the past 6 months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of a single intra-articular injection of hydrolyzed collagen compared to a placebo (saline solution) in patients with knee osteoarthritis. A total of 204 participants will be randomly assigned to receive either the collagen injection or the placebo, with follow-up assessments conducted at 1, 3, and 6 months post-injection. Clinical evaluations will include both subjective questionnaires and objective measures such as thermographic assessments to monitor inflammation. After 6 months, participants in the placebo group will have the option to switch to the collagen treatment for an additional 6 months of follow-up.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for managing knee osteoarthritis symptoms.
How similar studies have gone: While similar approaches have been explored, this specific formulation and method of administration is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Unilateral involvement; 2. Signs and symptoms of degenerative pathology of knee cartilage; 3. Radiographic and MRI signs of degenerative pathology of the knee cartilage (Kellgren-Lawrence 1-4 grades); 4. Failure, defined as the persistence of symptoms, after at least one course of conservative treatment (pharmacological, physiotherapeutic or infiltrative treatment); 5. Ability and consent of patients to actively participate in clinical follow-up; Exclusion Criteria: 1. Patients who have undergone intra-articular injections of another substance in the previous 6 months; 2. Patients undergoing knee surgery within the previous 12 months; 3. Patients with malignant neoplasms; 4. Patients with rheumatic diseases; 5. Patients with diabetes; 6. Patients with hematologic diseases (coagulopathies); 7. Patients on anticoagulant therapy; 8. Patients with metabolic disorders of the thyroid gland; 9. Patients abusing alcoholic beverages, drugs or medications; 10. Body Mass Index \> 35; 11. Pregnant or lactating women. 12. Patients with established hypersensitivity to bovine collagen or vitamin C. 13. Patients with joint or peri-articular infections, emarto, erythema, or psoriatic patches in the knee joint area
Where it's running
-
Istituto Ortopedico Rizzoli
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Alessandro Di Martino, MD — Istituto Ortopedico Rizzoli
- Study coordinator: Roberta Licciardi, Msc
- Email: roberta.licciardi@ior.it
- Phone: 0516366567
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of virtual reality on walking in adults with knee osteoarthritis
This study tests how immersive virtual reality environments—designed to feel safe or to provoke fear—affect walking and worry about movement in adults 50 and older with knee osteoarthritis and in healthy peers.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
Preoperative Multimorbidity and Functional Recovery After Total Knee Arthroplasty
This study tests whether higher burden of preoperative multimorbidity affects functional recovery after knee replacement in adults with knee osteoarthritis.
-
Cartilage biomarker response to acute loading in knee OA by antiresorptive treatment status
Researchers will test whether a 30-minute treadmill walk changes cartilage biomarkers in postmenopausal women with knee osteoarthritis, comparing those on denosumab, bisphosphonates, and those not on antiresorptives.
-
Lysyl Enzymes in Knee Osteoarthritis
This study tests whether blood levels of lysyl hydroxylase and lysyl oxidase differ between people with knee osteoarthritis and healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.